Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report

BACKGROUND: Lenvatinib is a tyrosine kinase inhibitor with novel binding ability. It is considered the standard of care for metastatic thyroid cancer; moreover, whether it is indicated for other malignant tumors has been examined. Lenvatinib increases the risk of kidney injury in some patients. In c...

Descripción completa

Detalles Bibliográficos
Autores principales: Furuto, Yoshitaka, Hashimoto, Hirotsugu, Namikawa, Akio, Outi, Haruki, Takahashi, Hiroko, Horiuti, Hajime, Honda, Kazuho, Shibuya, Yuko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194623/
https://www.ncbi.nlm.nih.gov/pubmed/30340546
http://dx.doi.org/10.1186/s12882-018-1074-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194623/
https://www.ncbi.nlm.nih.gov/pubmed/30340546
http://dx.doi.org/10.1186/s12882-018-1074-3

Ejemplares similares